Company Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories.
The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 267 |
| CEO | Michael G. Raab |
Contact Details
Address: 34175 Ardenwood Blvd. Fremont, California 94555 United States | |
| Phone | 510-745-7047 |
| Website | ardelyx.com |
Stock Details
| Ticker Symbol | ARDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001437402 |
| CUSIP Number | 039697107 |
| ISIN Number | US0396971071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Raab | President, Chief Executive Officer and Director |
| Susan Rodriguez | Chief Commercial Officer |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer |
| Justin A. Renz CPA, MBA | Chief Financial and Operations Officer and Treasurer |
| Robert Felsch | Senior Vice President of Finance and Chief Accounting Officer |
| Elizabeth A. Grammer Esq. | Chief Legal and Administrative Officer and Secretary |
| Caitlin Lowie | Vice President of Corporate Communications and Investor Relations |
| Mike Kelliher | Executive Vice President of Corporate Development and Strategy |
| Charon Spencer Sr. | Chief Human Resources Officer |
| David P. Rosenbaum | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2024 | 144 | Filing |
| May 3, 2024 | 144 | Filing |
| May 3, 2024 | 144 | Filing |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 29, 2024 | 144 | Filing |
| Apr 15, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |